195 related articles for article (PubMed ID: 8245881)
1. Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus.
Purifoy DJ; Beauchamp LM; de Miranda P; Ertl P; Lacey S; Roberts G; Rahim SG; Darby G; Krenitsky TA; Powell KL
J Med Virol; 1993; Suppl 1():139-45. PubMed ID: 8245881
[TBL] [Abstract][Full Text] [Related]
2. Acyclovir--and beyond.
Darby G
J Int Med Res; 1994; 22 Suppl 1():33A-42A. PubMed ID: 8063023
[TBL] [Abstract][Full Text] [Related]
3. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections.
Perry CM; Faulds D
Drugs; 1996 Nov; 52(5):754-72. PubMed ID: 9118821
[TBL] [Abstract][Full Text] [Related]
4. Lack of interaction between valaciclovir, the L-valyl ester of acyclovir, and Maalox antacid.
de Bony F; Bidault R; Peck R; Posner J
J Antimicrob Chemother; 1996 Feb; 37(2):383-7. PubMed ID: 8707752
[TBL] [Abstract][Full Text] [Related]
5. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy.
Beutner KR
Antiviral Res; 1995 Dec; 28(4):281-90. PubMed ID: 8669888
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships for dipeptide prodrugs of acyclovir: implications for prodrug design.
Santos CR; Capela R; Pereira CS; Valente E; Gouveia L; Pannecouque C; De Clercq E; Moreira R; Gomes P
Eur J Med Chem; 2009 Jun; 44(6):2339-46. PubMed ID: 18848738
[TBL] [Abstract][Full Text] [Related]
7. New antivirals with activity against varicella-zoster virus.
Gnann JW
Ann Neurol; 1994; 35 Suppl():S69-72. PubMed ID: 8185303
[TBL] [Abstract][Full Text] [Related]
8. Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea.
Anand B; Nashed Y; Mitra A
Curr Eye Res; 2003; 26(3-4):151-63. PubMed ID: 12815543
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of 2-amino-6-fluoro-9-(2-hydroxyethoxymethyl)purine esters as potential prodrugs of acyclovir.
Kim DK; Lee N; Im GJ; Kim HT; Kim KH
Bioorg Med Chem; 1998 Dec; 6(12):2525-30. PubMed ID: 9925308
[TBL] [Abstract][Full Text] [Related]
10. Cyclopropanecarboxylic acid esters as potential prodrugs with enhanced hydrolytic stability.
Bender DM; Peterson JA; McCarthy JR; Gunaydin H; Takano Y; Houk KN
Org Lett; 2008 Feb; 10(3):509-11. PubMed ID: 18181639
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers.
Weller S; Blum MR; Doucette M; Burnette T; Cederberg DM; de Miranda P; Smiley ML
Clin Pharmacol Ther; 1993 Dec; 54(6):595-605. PubMed ID: 8275615
[TBL] [Abstract][Full Text] [Related]
12. Successful kinase bypass with new acyclovir phosphoramidate prodrugs.
McGuigan C; Derudas M; Bugert JJ; Andrei G; Snoeck R; Balzarini J
Bioorg Med Chem Lett; 2008 Aug; 18(15):4364-7. PubMed ID: 18614365
[TBL] [Abstract][Full Text] [Related]
13. Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the L-valyl ester prodrug of acyclovir.
Burnette TC; Harrington JA; Reardon JE; Merrill BM; de Miranda P
J Biol Chem; 1995 Jun; 270(26):15827-31. PubMed ID: 7797586
[TBL] [Abstract][Full Text] [Related]
14. Valacyclovir.
Acosta EP; Fletcher CV
Ann Pharmacother; 1997 Feb; 31(2):185-91. PubMed ID: 9034421
[TBL] [Abstract][Full Text] [Related]
15. Antiviral therapy of herpes simplex and varicella-zoster virus infections.
Wutzler P
Intervirology; 1997; 40(5-6):343-56. PubMed ID: 9675639
[TBL] [Abstract][Full Text] [Related]
16. Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides.
Andrei G; Sienaert R; McGuigan C; De Clercq E; Balzarini J; Snoeck R
Antimicrob Agents Chemother; 2005 Mar; 49(3):1081-6. PubMed ID: 15728906
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of some masked phosphate esters of the anti-herpesvirus drug 882C (netivudine) as potential antiviral agents.
McGuigan C; Perry A; Yarnold CJ; Sutton PW; Lowe D; Miller W; Rahim SG; Slater MJ
Antivir Chem Chemother; 1998 May; 9(3):233-43. PubMed ID: 9875402
[TBL] [Abstract][Full Text] [Related]
18. Stability of valacyclovir: implications for its oral bioavailability.
Granero GE; Amidon GL
Int J Pharm; 2006 Jul; 317(1):14-8. PubMed ID: 16759825
[TBL] [Abstract][Full Text] [Related]
19. A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein.
Kim I; Song X; Vig BS; Mittal S; Shin HC; Lorenzi PJ; Amidon GL
Mol Pharm; 2004; 1(2):117-27. PubMed ID: 15832508
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster.
Lin WR; Lin HH; Lee SS; Tsai HC; Huang CK; Wann SR; Chen YS; Chiang SC; Yen MY; Liu YC
J Microbiol Immunol Infect; 2001 Jun; 34(2):138-42. PubMed ID: 11456360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
